Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable

References

• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018 Mar 31;391(10127):1285–1300. doi: 10.1016/S0140-6736(17)33293-2
   PubMed Web of Science ®Google Scholar
• Langer J, Welch VL, Moran MM, et al. High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review. Adv Ther. 2023 Apr;40(4):1601–1627. doi: 10.1007/s12325-023-02432-1
   PubMedGoogle Scholar
• Schmid P, Rauber D, Betsch C, et al. Barriers of influenza vaccination Intention and behavior - a systematic review of influenza vaccine hesitancy, 2005 - 2016. PLoS One. 2017;12(1):e0170550.
   PubMed Web of Science ®Google Scholar
• Nab L, Parker EPK, Andrews CD, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023 May;8(5):e364–e377. doi: 10.1016/S2468-2667(23)00079-8
   PubMed Web of Science ®Google Scholar
• Xie Y, Choi T, Al-Aly Z. Risk of death in patients hospitalized for COVID-19 vs seasonal influenza in fall-winter 2022-2023. JAMA. 2023 May 16;329(19):1697–1699.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. How coronavirus (COVID-19) compares with flu and pneumonia as a cause of death 2023. [cited 2023 May 25]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/howcoronaviruscovid19compareswithfluasacauseofdeath/2022-05-23
   Google Scholar
• Tokars JI, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511–1518.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States—2018–2019 influenza season 2021. [updated 2021 Sep 29; cited 2023 Jul 3]. Available from: https://www.cdc.gov/flu/about/burden/2018-2019.html
   Google Scholar
• de Courville C, Cadarette SM, Wissinger E, et al. The economic burden of influenza among adults aged 18 to 64: a systematic literature review. Influenza Other Respir Viruses. 2022 May;16(3):376–385. doi: 10.1111/irv.12963
   PubMed Web of Science ®Google Scholar
• Near AM, Tse J, Young-Xu Y, et al. Burden of influenza hospitalization among high-risk groups in the United States. BMC Health Serv Res. 2022 Sep 28;22(1):1209. doi: 10.1186/s12913-022-08586-y
   PubMed Web of Science ®Google Scholar
• Kim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 2018 Mar;31(2):174–183. doi: 10.1089/vim.2017.0141
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. How flu viruses can change: “drift” and “shift” 2022 [updated 2022 Dec 12; cited 2023 May 17]. Available from: https://www.cdc.gov/flu/about/viruses/change.htm#
   Google Scholar
• Harding AT, Heaton NS. Efforts to improve the seasonal influenza vaccine. Vaccines (Basel). 2018 Mar 30;6(2):19.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. The 2009 H1N1 pandemic: summary highlights, April 2009–April 2010 2010. [cited 2021 Nov 30]. Available from: https://www.cdc.gov/h1n1flu/cdcresponse.htm
   Google Scholar
• World Health Organization. Evolution of a pandemic: a(H1N1) 2009. April 2009 – March 2010. Geneva: World Health Organization; 2010.
   Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: World Health Organization; 2023 [updated 2023 Feb 24; cited 2023 May 17]. Available from: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2023-2024/202302_seasonal_recommendation_a.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Influenza historic timeline 2019 [updated 2019 Jan 30; cited 2023 May 18]. Available from: https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm
   Google Scholar
• Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 Feb;10(2):83–92. doi: 10.1016/S1473-3099(09)70331-7
   PubMed Web of Science ®Google Scholar
• Behrouzi B, Bhatt DL, Cannon CP, et al. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e228873. doi: 10.1001/jamanetworkopen.2022.8873
   PubMed Web of Science ®Google Scholar
• National Foundation for Infectious Diseases. Call to action: the dangers of influenza and benefits of vaccination in adults with chronic health conditions 2018 [updated 2018 Sep; cited 2023 May 15]. Available from: https://www.nfid.org/wp-content/uploads/2019/08/cta-dangers-of-influenza-in-adults-with-chronic-health-c.pdf
   Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022 Aug 26;71(1):1–28. doi: 10.15585/mmwr.rr7101a1
   PubMedGoogle Scholar
• UK Health and Security Agency. Guidance: the flu vaccination: who should have it and why 2022. [updated 2022 Nov 11; cited 2023 Mar 27]. Available from: https://www.gov.uk/government/publications/flu-vaccination-who-should-have-it-this-winter-and-why/the-flu-vaccination-who-should-have-it-and-why
   Google Scholar
• European Centre for Disease Prevention and Control. Factsheet about seasonal influenza 2022 [Updated 2022 Apr 12; cited 2023 Apr 18]. Available from: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
   Google Scholar
• Rizzo C, Rezza G, Ricciardi W. Strategies in recommending influenza vaccination in Europe and US. Human Vaccines Immunother. 2018 Mar 4;14(3):693–698.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccines against influenza: WHO position paper—May 2022. Releve epidemiologique hebdomadaire. 2022 May 13;97(19):185–208.
   Google Scholar
• Belongia EA, Sundaram ME, McClure DL, et al. Waning vaccine protection against influenza a (H3N2) illness in children and older adults during a single season. Vaccine. 2015 Jan 1;33(1):246–251. doi: 10.1016/j.vaccine.2014.06.052
   PubMed Web of Science ®Google Scholar
• Kissling E, Nunes B, Robertson C, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016 Apr 21;21(16). doi: 10.2807/1560-7917.Es.2016.21.16.30201
   Google Scholar
• Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, et al. Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine. 2017 Oct 13;35(43):5799–5807. doi: 10.1016/j.vaccine.2017.09.035
   PubMed Web of Science ®Google Scholar
• Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016 Aug;16(8):942–951. doi: 10.1016/S1473-3099(16)00129-8
   PubMed Web of Science ®Google Scholar
• Rajaram S, Wojcik R, Moore C, et al. The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: literature review and expert consensus. Vaccine. 2020 Aug 27;38(38):6047–6056. doi: 10.1016/j.vaccine.2020.06.021
   PubMed Web of Science ®Google Scholar
• Belongia EA, McLean HQ. Influenza vaccine effectiveness: defining the H3N2 problem. Clinical infectious diseases: an official publication of the infectious diseases Society of America. Clinl Infect Dis. 2019 Oct 30;69(10):1817–1823.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012 Oct;55(7):951–959. doi: 10.1093/cid/cis574
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb;58(3):319–27. doi: 10.1093/cid/cit736
   PubMed Web of Science ®Google Scholar
• McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15;211(10):1529–1540. doi: 10.1093/infdis/jiu647
   PubMed Web of Science ®Google Scholar
• Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis. 2016 May 15;213(10):1546–56. doi: 10.1093/infdis/jiv577
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Nowalk MP, Chung J, et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis. 2016 Dec 15;63(12):1564–1573. doi: 10.1093/cid/ciw635
   PubMed Web of Science ®Google Scholar
• Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med. 2017 Aug 10;377(6):534–543. doi: 10.1056/NEJMoa1700153
   PubMed Web of Science ®Google Scholar
• Flannery B, Chung JR, Monto AS, et al. Influenza vaccine effectiveness in the United States during the 2016-2017 season. Clin Infect Dis. 2019 May 17;68(11):1798–1806. doi: 10.1093/cid/ciy775
   PubMed Web of Science ®Google Scholar
• Rolfes MA, Flannery B, Chung JR, et al. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. Clin Infect Dis. 2019 Nov 13;69(11):1845–1853. doi: 10.1093/cid/ciz075
   PubMed Web of Science ®Google Scholar
• Flannery B, Kondor RJG, Chung JR, et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season. J Infect Dis. 2020 Jan 1;221(1):8–15. doi: 10.1093/infdis/jiz543
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Kondor RJG, Chung JR, et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States-2019-2020. Clin Infect Dis. 2021 Dec 6;73(11):e4244–e4250. doi: 10.1093/cid/ciaa1884
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden 2022 updated 2022 Oct 18; cited 2023 Jun 27]. Available from:https://www.cdc.gov/flu/about/burden/past-seasons.html
   Google Scholar
• Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States—2017–2018 influenza season Atlanta (GA): US Department of Health and Human Services; 2021 [updated 2021 Sep 30; cited 2023 Jul 3]. Available from: https://www.cdc.gov/flu/about/burden/2017-2018.htm
   Google Scholar
• Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States—2019–2020 influenza season 2021 [updated 2021 Oct 1; cited 2023 Jul 3]. Available from: https://www.cdc.gov/flu/about/burden/2019-2020.html
   Google Scholar
• Chen C, Liu X, Yan D, et al. Global influenza vaccination rates and factors associated with influenza vaccination. Int J Infect Dis. 2022 Dec;125:153–163.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Influenza Programme 2023 [cited 2023 May 17]. Available from: https://www.who.int/teams/global-influenza-programme
   Google Scholar
• Monto AS. Reflections on the Global influenza surveillance and Response system (GISRS) at 65 years: an expanding framework for influenza detection, Prevention and Control. Influenza Other Respir Viruses. 2018 Jan;12(1):10–12. doi: 10.1111/irv.12511
   PubMed Web of Science ®Google Scholar
• Beyer WE, McElhaney J, Smith DJ, et al. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013 Dec 5;31(50):6030–3. doi: 10.1016/j.vaccine.2013.09.063
   PubMed Web of Science ®Google Scholar
• Koel BF, Mögling R, Chutinimitkul S, et al. Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses. J Virol. 2015 Apr;89(7):3763–3775. doi: 10.1128/JVI.02962-14
   PubMed Web of Science ®Google Scholar
• Koel BF, Burke DF, Bestebroer TM, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013 Nov 22;342(6161):976–979. doi: 10.1126/science.1244730
   PubMed Web of Science ®Google Scholar
• Takla A, Wichmann O, Carrillo-Santisteve P, et al. Characteristics and practices of national immunisation technical Advisory groups in Europe and potential for collaboration, April 2014. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. Eurosurveillance. 2015 Mar 5;20(9): doi: 10.2807/1560-7917.ES2015.20.9.21049
   Web of Science ®Google Scholar
• Harder T. The German Standing Committee on vaccination: organization and mode of functioning. Z Rheumatol. 2020 Nov;79(9):839–847. doi: 10.1007/s00393-020-00857-5
   PubMed Web of Science ®Google Scholar
• Harder T, Koch J, von Kries R, et al. The new standard operating procedure of the German standing committee on vaccination (STIKO): history, structure, and implementation. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Apr;62(4):392–399. doi: 10.1007/s00103-019-02898-x
   PubMed Web of Science ®Google Scholar
• Robert Koch Institute. Recommendations by the Standing Committee on vaccination (STIKO) at the Robert Koch Institute – 2023 2023 [updated 2023 Jul 21; cited 2023 Aug 21]. Available from: https://www.rki.de/EN/Content/infections/Vaccination/recommandations/04_23_englisch.pdf
   Google Scholar
• Government of Spain, Ministry of health. Spanish Network Of Agencies For The Evaluation Of Health Technologies And Benefits Of The National Health System 2021 [cited 2023 May 19]. Available from: https://redets.sanidad.gob.es
   Google Scholar
• Limia Sánchez A, Olmedo Lucerón C, Soler Soneira M, et al. Ponencia de Programa y Registro de Vacunaciones y evolución del calendario de vacunación en España. Rev Esp Salud Publica. 2020 Mar 11;94:202003018.
   Google Scholar
• García FJ Á, Cilleruelo Ortega MJ, Álvarez AJ, et al. Immunisation schedule of the Spanish Association of Paediatrics: 2023 recommendations. An Pediatr (Engl Ed). 2023 Jan;98(1):58.e1–58.e10. doi: 10.1016/j.anpede.2022.11.002
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad. Vacunas y Programa de Vacunación: gripe. 2023 [cited 2023 May 20]. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/vacunas/profesionales/gripe.htm
   Google Scholar
• Ministerio de Sanidad. Vacunas y Programa de Vacunación: Ponencia de Programa y Registro de Vacunaciones 2023 [cited 2023 May 22]. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/ponencia.htm
   Google Scholar
• Ministerio de Sanidad. Portal estadístico: Área de inteligencia de gestión. SIVAMIN: cobertura de vacunación. 2023 [cited 2023 May 22]. Available from: https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/I/sivamin/sivamin
   Google Scholar
• Ponencia de Programa y Registro de Vacunaciones. Recomendaciones de vacunacion frente a la gripe en poblacion infantil de 6 a 59 meses: Government of Spain. 2022 [cited2023 Dec 5]. Availabe from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/programasDeVacunacion/docs/Recomendaciones_vacunacion_gripe_PoblacionInfantil.pdf
   Google Scholar
• Diariofarma. Las primeras CC.AA. en realizar la vacunación antigripal en niños alcanzan coberturas de más del 40% 2023 [updated 2023 Feb 27; cited 2023 May 22]. Available from: https://diariofarma.com/2023/02/27/las-primeras-cc-aa-en-realizar-la-vacunacion-antigripal-en-ninos-alcanzan-coberturas-de-mas-del-40
   Google Scholar
• Joint Committe on Vaccination and Immunisation. Advice on influenza vaccines for 2023/24 2022 [updated 2022 Nov; cited 2023 May 20]. Available from: https://app.box.com/s/t5ockz9bb6xw6t2mrrzb144njplimfo0/file/1079253178131
   Google Scholar
• UK Health and Security Agency. Guidance: national flu immunisation programme 2023 to 2024 letter 2023 [updated 2023 May 25; cited 2023 Jun 6]. Available from: https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan/national-flu-immunisation-programme-2023-to-2024-letter
   Google Scholar
• Joint Committe on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination London: Department Of Health And Social Care; 2023 [cited 2023 May 20]. Available from: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#influenza-vaccines-jcvi-advice
   Google Scholar
• Ministero della Salute. Piano Nazionale Prevenzione Vaccinale: 2023-2025. 2023 [cited 2023 May 22]. Available from: https://www.quotidianosanita.it/allegati/allegato1679488094.pdf
   Google Scholar
• Ministero della Salute. Direzione Generale Della Prevenzione Sanitaria. Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2023-2024 2023 [updated 2023 Apr 21; cited 2023 Apr 21]. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=93294&parte=1%20&serie=null
   Google Scholar
• Robert Koch Institute. Report on the epidemiology of influenza in Germany 2019 [updated 2019 Sep 30; cited 2023 May 20]. Available from: https://www.rki.de/EN/Content/infections/epidemiology/inf_dis_Germany/influenza/influenza_germany/Report_Influenza.html
   Google Scholar
• Paul-Ehrlich-Institut. In­fluen­za vac­cines (all mar­ket­ing au­tho­ri­sa­tions) 2023. https://www.pei.de/EN/medicinal-products/vaccines-human/influenza-flu/influenza-flu-node.html
   Google Scholar
• I-MOVE: Influenza—Monitoring Vaccine Effectiveness in Europe 2021 [cited 2023 May 22]. Available from: https://www.imoveflu.org
   Google Scholar
• Puig-Barberà J. 2010-2011 influenza seasonal vaccine, preliminary mid-season effectiveness estimates: reason for concern, confounding or are we following the right track? Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2011 Mar 17; 16(11): doi: 10.2807/ese.16.11.19821-en
   Google Scholar
• Rose A, Kissling E, Emborg HD, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. Eurosurveillance. 2020 Mar;25(10). doi: 10.2807/1560-7917.ES.2020.25.10.2000153
   Google Scholar
• Machado A, Mazagatos C, Dijkstra F, et al. Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. Euro Surveill. 2019 Nov; 24(45):1900268. doi: 10.2807/1560-7917.ES.2019.24.45.1900268
   PubMedGoogle Scholar
• Instituto de Salud Carlos III. Sistema de Vigilancia de la Gripe en España 2022 [cited 2023 May 22]. Available from: https://vgripe.isciii.es/inicio.do
   Google Scholar
• Instituto de Salud Carlos III. Vigilancia de gripe y otros virus respiratorios en España. Sistemas y fuentes de información: temporada 2020-2021 2022 [cited 2023 May 22]. Available from: https://vgripe.isciii.es/documentos/20202021/home/Sistemas%20y%20fuentes%20de%20informacion%20del%20SVGE_2020-21_vf.pdf
   Google Scholar
• Martínez-Baz I, Casado I, Miqueleiz A, et al. Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2022 Jun; 27(26). doi: 10.2807/1560-7917.ES.2022.27.26.2200488
   Google Scholar
• Mira-Iglesias A, López-Labrador FX, Baselga-Moreno V, et al. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2019 Aug; 24(31). doi: 10.2807/1560-7917.ES.2019.24.31.1800461
   Google Scholar
• Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, et al. Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. Eurosurveillance. 2015 Jul 16;20(28): doi: 10.2807/1560-7917.ES2015.20.28.21187
   Web of Science ®Google Scholar
• Godoy P, Romero A, Soldevila N, et al. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. Eurosurveillance. 2018 Oct;23(43). doi: 10.2807/1560-7917.ES.2018.23.43.1700732
   Google Scholar
• European Centre for Disease Prevention and Control. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory- confirmed influenza in individuals aged 18 years and over Stockholm: ECDC; 2020 [cited 2023 May 22]. Available from: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-systematic-review-efficacy-vaccines
   Google Scholar
• UK Health and Security Agency. Seasonal influenza: guidance, data and analysis 2023 [cited 2023 May 22]. Available from: https://www.gov.uk/government/collections/seasonal-influenza-guidance-data-and-analysis
   Google Scholar
• National Health Service England. Guidance: National Flu Immunisation Programme 2022 to 2023 letter 2022 [updated 2022 Jul 22; cited 2023 May 22]. Available from: https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan
   Google Scholar
• Calabrò GE, Boccalini S, Panatto D, et al. The new quadrivalent adjuvanted influenza vaccine for the Italian elderly: a health technology assessment. Int J Environ Res Public Health. 2022 Mar 31;19(7):4166. doi: 10.3390/ijerph19074166
   PubMed Web of Science ®Google Scholar
• Calabrò GE, Boccalini S, Bechini A, et al. Health technology assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax tetra(®) 2.0. J Prev Med Hyg. 2022 Dec;63(4 Suppl 1):E1–e140.
   Google Scholar
• Calabrò GE, Boccalini S, Bonanni P, et al. Valutazione di Health Technology Assessment (HTA) del vaccino antinfluenzale quadrivalente adiuvato: Fluad Tetra 2021 [cited 2023 May 23]. Available from: https://www.ijph.it/hta-vaccino-antinfluenzale-quadrivalente-adiuvato-fluad-tetra
   Google Scholar
• Boccalini S, Pariani E, Calabrò GE, et al. Health Technology assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz tetra(®). J Prev Med Hyg. 2021 Jun;62(2 Suppl 1):E1–e118.
   Google Scholar
• DRIVE – Development of Robust and Innovative Vaccine Effectiveness. Increasing understanding of influenza vaccine effectiveness in Europe 2023 [cited 2023 Jul 2]. Available from: https://www.drive-eu.org
   Google Scholar
• Schmitt HJ, Saidu Y, Hrynkevych K, et al. The formal ability of countries to deliver high-quality vaccination services: introducing the country vaccination score (CVS). VacciReview. 2022;9(1):1–14.
   Google Scholar
• European Centre for Disease Prevention and Control. ECDC Vaccine Effectiveness, Burden and Impact Studies (VEBIS) for COVID-19 and Influenza 2023 [cited 2023 Jul 2]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/SBacci.pdf
   Google Scholar
• Advisory Committee on Immunization Practices. Evidence to recommendations (EtR) framework: higher dose and adjuvanted influenza vaccines for persons aged ≥65 years Atlanta: Centers for Disease Control and Prevention; 2022 [updated 2022 Aug 24; cited 2023 Oct 18]. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/influenza-older-adults-etr.html
   Google Scholar
• Advisory Committee on Immunization Practices. GRADE: higher dose and adjuvanted influenza vaccines for persons aged ≥65 years Atlanta: Centers for Disease Control and Prevention; 2022 [updated 2022 Aug 24; cited 2023 Oct 18]. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/influenza-older-adults.html
   Google Scholar
• Grohskopf L Influenza vaccines for older adults: GRADE summary Atlanta: Centers for Disease Control and Prevention; 2022 [updated 2023 Feb 23; cited 2023 Oct 18]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-23-24/04-influenza-grohskopf-508.pdf
   Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 influenza season. MMWR Recomm Rep. 2023;72(2):1–25.
   Google Scholar
• Collins R, Bowman L, Landray M, et al. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020 Feb 13;382(7):674–678. doi: 10.1056/NEJMsb1901642
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343(oct18 2):d5928. doi: 10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Beran J, Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis. 2009 Jan 17;9(1):2. doi: 10.1186/1471-2334-9-2
   PubMedGoogle Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021 May;109(5):1212–1218. doi: 10.1002/cpt.2083
   PubMed Web of Science ®Google Scholar
• Wang SV, Schneeweiss S, Franklin JM, et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023 Apr 25;329(16):1376–1385. doi: 10.1001/jama.2023.4221
   PubMed Web of Science ®Google Scholar
• World Health Organization. Evaluation of influenza vaccine effectiveness 2017 [cited Oct 7]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255203/9789241512121-eng.pdf;sequence=1
   Google Scholar
• Ferrara P, Mantovani LG. The importance of real-world evidence in understanding influenza vaccine effectiveness. Farmeconomia, Health Econ Ther Pathways. 2022;23(1):29–32. doi: 10.7175/fe.v23i1.1522
   Web of Science ®Google Scholar
• Orsini LS, Monz B, Mullins CD, et al. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1504–1513. doi: 10.1002/pds.5079
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003 Sep;73(9):712–716. doi: 10.1046/j.1445-2197.2003.02748.x
   PubMed Web of Science ®Google Scholar
• Schad F, Thronicke A. Real-world evidence—Current developments and perspectives. IJERPH. 2022 Aug 16;19(16):10159.
   Web of Science ®Google Scholar
• Cole A, Webster P, Van Liew D, et al. Safety surveillance and challenges in accelerated COVID-19 vaccine development. Ther Adv Drug Saf. 2022;13:20420986221116452. doi: 10.1177/20420986221116452
   Web of Science ®Google Scholar
• Singh JA, Kochhar S, Wolff J, et al. WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: ethical considerations. Vaccine. 2022 Mar 25;40(14):2140–2149. doi: 10.1016/j.vaccine.2022.02.038
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 May 13;373(n1088): doi: 10.1136/bmj.n1088
   PubMedGoogle Scholar
• Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022 Mar 5;399(10328):924–944. doi: 10.1016/S0140-6736(22)00152-0
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022 Apr 21;386(16):1532–1546. doi: 10.1056/NEJMoa2119451
   PubMed Web of Science ®Google Scholar
• Rudolph A, Mitchell J, Barrett J, et al. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Ther Adv Drug Saf. 2022;13:20420986221118972. doi: 10.1177/20420986221118972
   Web of Science ®Google Scholar
• Dreyer NA, Velentgas P, Westrich K, et al. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J Managed Care Specialty Pharm. 2014 Mar;20(3):301–8. doi: 10.18553/jmcp.2014.20.3.301
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383–94. doi: 10.1016/j.jclinepi.2010.04.026
   PubMed Web of Science ®Google Scholar
• Moberg J, Oxman AD, Rosenbaum S, et al. The GRADE evidence to decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018 May 29;16(1):45. doi: 10.1186/s12961-018-0320-2
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. ACIP evidence to recommendations framework [cited 25 May 2023]. Available from: https://www.cdc.gov/vaccines/acip/recs/grade/downloads/acip-evidence-recs-framework.pdf
   Google Scholar
• European Commission. Health technology assessment overview 2023 cited 25 May 2023]. Available from: https://health.ec.europa.eu/health-technology-assessment/overview_en#
   Google Scholar
• Cuello-Garcia CA, Santesso N, Morgan RL, et al. GRADE guidance 24 optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines. J Clin Epidemiol. 2022 Feb;142:200–208.
   PubMed Web of Science ®Google Scholar
• Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014 Apr 29;2014(4):Mr000034.
   PubMedGoogle Scholar